Orforglipron, a novel non-peptide oral daily glucagon-like peptide-1 receptor agonist as an anti-obesity medicine: A systematic review and meta-analysis.

Deep Dutta Lakshmi NagendraBeatrice AnneManoj KumarMeha Sharma A B M Kamrul-Hasan

Published in: Obesity science & practice (2024)

Orforglipron at 24-45 mg/day doses is an effective weight loss medication. The efficacy versus side effect profile suggests that 24-36 mg/day is the most optimal dose for orforglipron as an anti-obesity medicine.

Keyphrases

weight loss
bariatric surgery
roux en y gastric bypass
insulin resistance
metabolic syndrome
weight gain
gastric bypass
high fat diet induced
type diabetes
physical activity
healthcare
glycemic control
obese patients
emergency department
body mass index
skeletal muscle